NCT00728858

Brief Summary

Nifedipine and barnidipine act as calcium channel blockers, and are widely prescribed for pressure control of prehypertension and stage 1 hypertension. CYP3A4 is responsible for the metabolism of nifedipine and nifedipine, while the contribution of CYP3A5 remains ambiguous. This study is aimed to analyze the association between antihypertensive effects of nifedipine as well as barnidipine and single nucleotide polymorphisms of CYP3A4, CYP3A5 and calcium channels.

Trial Health

100
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
43

participants targeted

Target at P25-P50 for all trials

Timeline
Completed

Started Apr 2006

Shorter than P25 for all trials

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

April 1, 2006

Completed
8 months until next milestone

Primary Completion

Last participant's last visit for primary outcome

December 1, 2006

Completed
2 months until next milestone

Study Completion

Last participant's last visit for all outcomes

February 1, 2007

Completed
1.3 years until next milestone

First Submitted

Initial submission to the registry

May 28, 2008

Completed
2 months until next milestone

First Posted

Study publicly available on registry

August 6, 2008

Completed
Last Updated

August 6, 2008

Status Verified

April 1, 2008

Enrollment Period

8 months

First QC Date

May 28, 2008

Last Update Submit

August 1, 2008

Conditions

Hypertension

Keywords

HypertensionSNPNifedipineBarnidipine

Eligibility Criteria

Age22 Years - 87 Years
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)
Sampling MethodProbability Sample
Study Population

Hypertension patients living in Taiwan

You may qualify if:

  • \~90 years old patient
  • mild to moderate hypertensive patients
  • can finish this study
  • can sign agreement

You may not qualify if:

  • severe hypertension
  • Heart failure, Arrhythmia
  • Liver or kidney failure
  • pregnant women
  • allergy to dihydropyridines
  • attend other clinical trials in past 3 month

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Biospecimen

Retention: SAMPLES WITH DNA

Extract DNA from buffy coat. Test drug concentration in plasma.

MeSH Terms

Conditions

Hypertension

Condition Hierarchy (Ancestors)

Vascular DiseasesCardiovascular Diseases

Study Officials

  • FU-TIEN CHIANG, Doctor

    National Taiwan University Hospital

    STUDY CHAIR

Study Design

Study Type
observational
Observational Model
CASE CONTROL
Time Perspective
PROSPECTIVE
Sponsor Type
OTHER

Study Record Dates

First Submitted

May 28, 2008

First Posted

August 6, 2008

Study Start

April 1, 2006

Primary Completion

December 1, 2006

Study Completion

February 1, 2007

Last Updated

August 6, 2008

Record last verified: 2008-04